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Background: Breastfeeding is a leading cause of infant HIV-1 infection in the developing world, yet only a minority
of infants exposed to HIV-1 via breastfeeding become infected. As a genetic bottleneck severely restricts the
number of postnatally-transmitted variants, genetic or phenotypic properties of the virus Envelope (Env) could be
important for the establishment of infant infection. We examined the efficiency of virologic functions required for
initiation of infection in the gastrointestinal tract and the neutralization sensitivity of HIV-1 Env variants isolated
from milk of three postnatally-transmitting mothers (n=13 viruses), five clinically-matched nontransmitting mothers
(n=16 viruses), and seven postnatally-infected infants (n = 7 postnatally-transmitted/founder (T/F) viruses).
Results: There was no difference in the efficiency of epithelial cell interactions between Env virus variants from the
breast milk of transmitting and nontransmitting mothers. Moreover, there was similar efficiency of DC-mediated
trans-infection, CCR5-usage, target cell fusion, and infectivity between HIV-1 Env-pseudoviruses from
nontransmitting mothers and postnatal T/F viruses. Milk Env-pseudoviruses were generally sensitive to
neutralization by autologous maternal plasma and resistant to breast milk neutralization. Infant T/F
Env-pseudoviruses were equally sensitive to neutralization by broadly-neutralizing monoclonal and polyclonal
antibodies as compared to nontransmitted breast milk Env variants.
Conclusion: Postnatally-T/F Env variants do not appear to possess a superior ability to interact with and cross a
mucosal barrier or an exceptional resistance to neutralization that define their capability to initiate infection across
the infant gastrointestinal tract in the setting of preexisting maternal antibodies.
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Mother to child transmission (MTCT) of HIV-1 via
breastfeeding is responsible for over a third of pediatric
HIV-1 infections in the developing world [1]. These post-
natal infections occur throughout the duration of breast-
feeding [2,3]. Interestingly, in the absence of antiretroviral
prophylaxis, less than 10% of breastfed infants born to
HIV-1-infected women acquire HIV-1 [2], despite many
months of exposure to large quantities of milk containing
cell-free and cell-associated virus [4,5]. As high levels of
maternal plasma virus load and low CD4 cell counts only
partially account for the risk of infant transmission [6], the
virion-host interactions required for this inefficient post-
natal transmission remain largely undefined. As with other
routes of MTCT [7-10], there is a genetic bottleneck that
restricts the number of virus variants transmitted through
breastfeeding to a single or a small number of variants
[11]. A comparative analysis of the genotypic and pheno-
typic characteristics of postnatally-transmitted and non-
transmitted HIV-1 variants is critical for understanding
the biologic mechanisms of postnatal HIV-1 transmission
and designing targeted prophylactic strategies.
Several groups have reported genetic differences between
transmitted and chronic HIV-1 Env variants [12-15]. For
example, heterosexually-transmitted clade C Env variants
have fewer putative N-linked glycosylation sites, more
compact variable loops, and are more sensitive to autolo-
gous neutralization [13]. Similarly, Env variants from
infants infected during delivery usually have shorter vari-
able loops and fewer glycosylation sites than maternal var-
iants [14]. Interestingly, the analysis of a large number of
clade B T/F env gene sequences has recently led to the
identification of putative transmission signature sequences
in the CCR5 binding site and gp160 signal peptide [16],
however, the functional significance of these transmitted
virus signature sequences remains ill-defined [17]. Muco-
sal transmission of clade B HIV-1 viruses has also been
associated with CD4+ T cell tropism and efficient CCR5
usage [18-20]. A superior ability of virions to perform key
steps required for mucosal invasion, such as high effi-
ciency binding to mucosal epithelial cells or enhanced
ability to be transferred by sub-epithelial DCs to CD4+ T
cells in the sub-mucosa or lymphoid tissue could confer a
selective advantage to HIV-1 variants during postnatal
transmission.
Novel anti-HIV-1 monoclonal antibodies (mAbs) cap-
able of neutralizing a broad spectrum of HIV-1 isolates
have recently been isolated [21-24] and could be useful
tools for passive immunization or for the design of active
immunization strategies to prevent MTCT. A protective
role of broadly-neutralizing antibodies in breast milk
HIV-1 acquisition has been established in non-human pri-
mates studies, as passive infusion of broadly-neutralizing
mAbs protected neonatal rhesus monkeys against oralchallenge with a simian-human immunodeficiency virus
[25,26]. However, previous studies have indicated that
viruses transmitted during breastfeeding are typically re-
sistant to neutralization by maternal autologous plasma
and broadly-neutralizing antibodies [11,27-29]. Neverthe-
less, the neutralization breadth of maternally- acquired
HIV-specific antibodies does not appear to correlate with
infant protection from postnatal HIV-1 acquisition [30].
Furthermore, Env variants from breast milk and plasma
appear to be equally-sensitive to autologous neutralization
[31]. Thus, a better understanding of the neutralizing
phenotype of breast milk viruses of postnatal-transmitting
women, including their sensitivity to the new generation
of broadly neutralizing mAbs, will help design immuno-
logic interventions to prevent postnatal HIV-1 acquisition.
While previous studies investigated the neutralization
phenotype of postnatally-transmitted viruses [11,32], no
previous studies have compared the genotype and
phenotype of breast milk Env variants from transmitting
and nontransmitting mothers. Moreover, previous inves-
tigations of infant T/F Env variants phenotype have not
included the assessment of the ability to interact with
and cross a mucosal barrier. Efficient interaction with
epithelial cells or tissue-associated DCs may be required
for HIV-1 transmission in the gastrointestinal tract. In
this study, we compare the genotype and function of 30
clade C Env variants isolated from the breast milk of
eight HIV-infected women who did or did not transmit
HIV-1 to their infants during breastfeeding and of 6 T/F
Env variants isolated from postnatally-infected infants.
Defining a phenotype of postnatally-transmitted virus var-
iants will guide the development of immunologic inter-
ventions to reduce HIV-1 transmission via breastfeeding.
Results
Selection of env variants from breast milk of postnatally-
transmitting and nontransmitting mothers and from
plasma of postnatally-infected infants
From a cohort of HIV-1-infected lactating women
(CHAVI 009) [33], HIV-1 env gene sequences were amp-
lified by SGA from milk collected at 4 to 6 weeks after
delivery from mothers who were confirmed to
postnatally-transmit HIV-1 to their infant (n = 3). Post-
natal infection was defined by a negative infant whole
blood HIV-1 DNA PCR at birth and four weeks of age
and a positive dried blood spot and/or whole blood
HIV-1 DNA PCR at three and/or six months of age.
HIV-1 env gene sequences were also amplified from the
milk of five nontransmitting HIV-1-infected, lactating
mothers (defined by a negative infant whole blood HIV-
1 DNA PCR at 9 months of age, following weaning, and
all prior time points) from the same cohort, matched for
maternal CD4 count and HIV-1 milk RNA viral load
(Table 1).The plasma virus load 4–6 weeks after delivery
Table 1 Maternal and infant clinical parameters
Subject Blood
CD4
count/ml
Plasma
VL RNA
copies/ml
Milk VL
RNA
copies/ml
(L and R)
Age of
infant at
HIV+ PCR
Postnatally-
transmitting
mothers
0404 80 22,600 29,650 6 mo
29,200
1209 153 3,070 635 6 mo
615
4403 208 100,892 101, 500 3 mo
30,450
Nontransmitting
mothers
0301 406 159,000 1,315 n/a
265
0702 523 35,200 31,900 n/a
2,530
3305 166 359,000 3,335 n/a
16,150
4707 247 83,400 10,500 n/a
22,500
5807 188 138,000 2,760 n/a
1,970
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mitting women and from 35,200 to 359,000 RNA cop-
ies/ml in nontransmitting women (p=0.14). Similarly,
there was no statistical difference in the milk virus load
of transmitting and nontransmitting women (milk virus
RNA copies/ml range 635 to 101,500 versus 1,315 to
31,900 in left breast and 615 to 30,450 versus 265 to
22,500 in right breast in transmitting and nontransmit-
ting women respectively, p=0.77 and 0.39). The range of
the plasma and milk virus loads was similar to that
observed in other studies [34]. The antibody response in
the plasma and milk of the study participants has been
previously reported [31].
HIV-1 env gene sequences were analyzed by maximum-
likelihood tree phylogenetic analysis [33]. Breast milk
HIV-1 env sequences without frameshift mutations or in-
frame stop codons representing distinct branches on the
phylogenetic trees were selected for cloning (Additional
file 1: Figure S1). When possible, env sequences were
selected from a group of identical or nearly identical env
sequences, as these sequences likely represent clonally-
amplified, functional viruses that recently-infected a local
target cell [33].
Two of the three postnatally-infected infants born to
the postnatally-transmitting mothers had adequate
plasma available following confirmation of infection in
the CHAVI 009 study for SGA amplification and se-
quencing of the infant plasma HIV-1 env sequences
(Figure 1). The infant of subject 4403 had plasma avail-
able at the same time point as the first positive HIV-1DNA PCR (3 months of age) (Figure 1B), whereas the
infant of subject 1209 did not have plasma available for
sequencing until 12 months of age, 6 months after the
initial positive HIV-1 DNA PCR (Figure 1A). These
infant sequences were phylogenetically compared to the
breast milk sequences from the transmitting mother.
The milk env variant of subject 4403 that was identical
to the T/F infant variant was well-defined to be 4403
bmC5 via phylogenetic (Figure 1B) and highlighter plot
(Figure 1C) analysis; this virus is part of a large group of
identical and nearly identical viruses in the milk of this
mother [33]. The maternal milk env variant in transmit-
ting mother 1209 that was most closely related to the
env sequences present in the infant six months following
infection was 1209 bmH5 (with a genetic distance of
1.4% from the matched infant consensus virus se-
quence). Thus, 4403 bmC5 milk variant represents the
infant postnatally T/F virus of 4403 and is included in
the analysis of infant postnatally-T/F viruses, whereas
1209 bmH5 milk variant only represents the sequenced
milk variant most closely related to the virus transmitted
to the 1209 infant.
Finally, the remaining six infant postnatally-T/F Env
variants were amplified from plasma or PBMCs collected
at 12 weeks of age of six Malawian infants who were
plasma HIV-1 DNA negative at birth and six weeks of
age, yet positive at 12 weeks of age, as described else-
where [35]. The cloned consensus of the infant env
sequences represented an inferred consensus sequence
of a virus present at or near the time of HIV-1 transmis-
sion, based on the Poisson-Fitter analysis, and thus are
referred to as infant T/F viruses [19].
Previously-defined T/F virus env signature sequence
patterns in env gene sequences from postnatal-
transmitting and nontransmitting mothers and
postnatally-infected infants
The presence of previously-defined putative T/F virus
env gene sequence signature patterns was assessed in
the env gene sequences of viruses cloned from the breast
milk of postnatally-transmitting and nontransmitting
mothers and from blood-derived env gene sequences of
six unpaired postnatally-infected infants, including: the
absence of a threonine at position 415 (H415) and the
absence of a histidine at position 12 in the Env signal se-
quence [16]. Neither of these genetic signatures, defined
in clade B adult T/F viruses, was common in the mater-
nal or infant virus variants in our cohort. Genetic signa-
tures identified in the sieve analysis of env V2 sequences
from the RV144 HIV vaccine trial [36] were also
assessed. Most postnatal T/F and milk variants had a ly-
sine residue at position 169 (7 of 7 postnatal T/F and 32
of 36 milk Env variants) and an isoleucine residue at
position 181 (6 of 7 postnatal T/F and 29 of 36 milk Env
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Figure 1 Phylogenetic comparison of virus env sequences from the plasma of postnatally-infected infants (red squares) and paired
mother’s milk (blue circles). The infant of maternal subject 1209 (A) was first HIV DNA positive at 6 months of age, but a plasma sample was
not available for virus sequencing until 12 months of age, thus infant virus evolution away from the transmitted maternal variant had occurred.
The infant of maternal subject 4403 (B) was first HIV DNA positive at 3 months of age and infant plasma virus sequencing was performed from a
sample collected at the same timepoint. The consensus of the infant plasma env sequences was confirmed to be identical to the maternal breast
milk variant 4403 bmC5 by highlight plot (C). The postnatally-T/F variant from subject 4403 and the maternal milk env variant most closely related
to the transmitted variant from subject 1209 are indicated with a red star.
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vaccine insert. We then investigated the presence of an
isoleucine at position 6 of the Env sequence that have
been reported to be prevalent in clade C env genes iso-
lated from HIV infected women who transmitted HIV in
utero as compared to nontransmitting women [37]. An
isoleucine at position 6 was observed in 12 of 13 (92%)
viruses from milk of postnatal-transmitting mothers, and
in 5 of 7 (71%) postnatally-T/F infant viruses but in only
12 of 23 (52%) viruses of nontransmitting mothers.
There was no difference in variable loop length (median
in transmitting mothers: 144, median in nontransmitting
mothers: 146, p=0.9) or number of potential N-linked
glycosylation sites (median in transmitting mothers:
28.5, median in nontransmitting mothers: 31, p=0.7)
between milk env variants from women who transmitted
or did not transmit HIV-1 to their infants during
breastfeeding.Breast milk Env variants from postnatal-transmitting and
nontransmitting mothers display similar efficiency of
binding to colonic epithelial cells and the putative HIV-1
epithelial cell attachment factor, galatosyl ceramide
(Galcer)
The initial steps of establishing a productive infection at
a mucosal surface requires HIV-1 virions to attach to
and cross a mucosal epithelial cell barrier. Thus, we
sought to determine if HIV-1 Env pseudovirus variants
from milk of women who postnatally-transmitted the
virus to their infant were more efficient in their ability
to attach to columnar gastrointestinal epithelial cells
(HT-29 cells) than those from women who did not
transmit the virus postnatally. We first determined if the
binding of Env variants to HT-29 cells was Env
dependent by assessing binding inhibition of HIV BAL
by the anti-HIV mAb IgG1B12 (25 ug/ml). The anti-
RSV mAb synagis was used a negative control. B12
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range of 40 to 60% as compared to synagis, indicating
that the interaction is a least partially Env dependent
(Figure 2A). The efficiency of breast milk HIV-1 Env
pseudovirus variant attachment to columnar epithelial
cells was between 0.3 and 2.1% and did not differ be-
tween postnatally-transmitting (Figure 2A) and non-
transmitting women (Figure 2B) (p = 0.9). Moreover,
neither the postnatally-T/F Env variant (4403 bmC5) nor
the breast milk Env variant most closely related to the
postnatally-transmitted variant (1209 bmH5) identified in
the milk of transmitting women had an unusually high ef-
ficiency to attach to columnar epithelial cells (Figure 2A).
Next, we assessed the ability of the gp120 Env proteins
expressed by the milk Env variants that had the highest
efficiency at binding to columnar epithelial cells (n = 9
Env variants from 3 transmitting mothers and 7 Env var-
iants from 3 nontransmitting mothers) to bind to Galcer,
the putative HIV epithelial cell attachment factor [38].A
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Figure 2 No difference in binding to colonic epithelial cells or galacto
and did not postnatally transmit HIV-1 to their infants. Binding of milk
mothers to colonic epithelial HT-29 cells. (C) Binding of gp120 proteins exp
interferometry. (D) Binding of gp120 variants from transmitting mothers to
standard deviation and lines represent means of two experiments performAgain, there was no difference in the efficiency of the
gp120 proteins expressed by HIV variants in milk of
transmitting and nontransmitting mothers to bind to
Galcer (Figure 2C). Moreover, the transmitted Env var-
iants did not have the strongest binding to Galcer when
compared to nontransmitted variants from the same
women (Figure 2D). Thus, we did not find evidence that
the ability of a virus Env to associate with colonic epi-
thelial cells or Galcer was a defining feature of viruses in
milk of postnatal-transmitting mothers.
Postnatally-transmitted Env variants are efficiently
transferred from mature DCs to CD4-expressing target
cells
The next early step that is likely to be important in
establishing productive mucosal infection is the inter-
action of HIV with DCs in the sub-epithelium of muco-
sal surfaces [39]. Virus-bound DCs are thought to traffic
virions to lymphoid tissue where they can productivelyB
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http://www.retrovirology.com/content/10/1/3infect CD4+ T cells. DC trans-infection of CD4+ T cells
appears to be dependent on interaction with the HIV
Env, as DC-mediated transfer to CD4-expressing re-
porter cells was inhibited by the glycan-dependent anti-
HIV-1 Env mAb 2 G12, as well as a CD4-inducible HIV-
neutralizing mAb isolated from colostrum B cells CH08
[40] (Mean Percent Inhibition (M.P.I) of 80.0 and 39.9%,
respectively) relative to an irrelevant anti-RSV mAb,
Synagis (Figure 3A). Breast milk is a rich source of anti-
lectin glycans and glycoproteins such as lactoferrin and
high mannose glycans [41,42], that have been shown to
interrupt the interaction of HIV Env with DC lectin
binding molecules [43,44]. Therefore, we assessed the
ability of lactoferrin (milk concentration 2.9 mg/ml,
range 1.3 to 6.9 mg/ml) [45] and α-methyl-D-mannopyr-
anoside (C7H14O6; free mannose milk concentration
42 ± 33 μM) [46] to inhibit the DC-transfer of an infant
T/F virus variant. Both reagents were inhibitory when
compared to the uninhibited virus control with an M.P.I
of 40.2% and 51.7% for lactoferrin and C7H14O6, respect-
ively (Figure 3B), confirming that breast milk containing
carbohydrates are able to inhibit DC-HIV interactions.
As the efficient virion interaction with DCs in the sub-
epithelial in the setting of carbohydrate-rich milk could
be a defining feature of postnatally-transmitted Env var-
iants, we sought to determine if postnatally-transmitted
HIV Env pseudovirus variants were more efficient in
their ability to bind to DCs and subsequently be trans-
ferred to permissive CD4+ cells compared to nontrans-
mitted variants. The efficiency of breast milk and infant
HIV-1 Env pseudovirus binding to DCs ranged between
0.3 and 1.6% (Figure 4A-C) and the efficiency of DC-
mediated trans-infection ranged between 0.03 and 2.9%
(Figure 4D-F). While there was no difference in the0.2
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Figure 3 DC transfer of breast milk HIV Env variants is at least partial
including human lactoferrin. (A) Virions were incubated with a blocking
incubated with mature DCs prior to inoculation of TZM-bl cells. DC transfe
anti-HIV Env mAbs 2 G12 and CH08 (A) relative to a non-HIV-specific contro
postnatally-transmitted infant-derived Env virus variant by α-methyl-D-man
respective uninhibited virus controls. Bars represent averages of three repli
inhibition (M.P.I) values relative to the appropriate controls are indicated.average binding efficiencies of breast milk Env pseudo-
virus variants from postnatally-transmitting and non-
transmitting women (p = 0.45), the postnatally-T/F Env
pseudoviruses were less efficient at binding to DCs com-
pared to the average DC-binding efficiency of milk var-
iants from nontransmitting women (p = 0.008).
However, this difference only trended towards significant
when correcting for multiple comparisons (q value 0.06).
This difference in binding efficiency of infant Env var-
iants and nontransmitted milk variants did not appear to
be attributable to interaction with DC-SIGN, as Env
variant binding to DC-SIGN-expressing cells both in
the presence and absence of mannan was similar
between infant T/F variants and breast milk Env variants
(Additional file 2: Figure S2).
Finally, we sought to determine if the relatively low
DC-binding efficiency of infant T/F variants affected
their ability to be transferred to CD4+ cells. Despite the
low DC binding-efficiency of the postnatally-T/F infant
Env pseudovirus variants, these infant viruses had DC
transfer efficiencies that trended towards higher than
that of Env variants from milk of nontransmitting
women (p = 0.06) (Figure 4F). However, breast milk var-
iants of transmitting and nontransmitting mothers had
similar DC-transfer efficiency (p = 0.10). We next
assessed the relationship between the number of glyco-
sylation sites on the Env protein and the efficiency of
Env variant DC-binding and transfer. There was no cor-
relation between the DC binding efficiencies of the
breast milk and infant Env pseudovirus variants and the
number of Env potential N-linked and O-linked glycosy-
lation sites (r=0.1, p = 0.6 and r=−0.07, p = 0.7 respect-
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http://www.retrovirology.com/content/10/1/3sites (r=−0.2, p = 0.3). In contrast, the transfer efficien-
cies of the breast milk and infant Env pseudovirus
variants positively correlated with the number of Env
O-linked glycosylation sites (r=0.4 p = 0.03), indicating a
potential link between the Env amino acid sequence,
glycosylation pattern, and DC-transfer efficiency.
As the glycosylation pattern of Env virions can be
influenced by the cell producing type [47], we compared
the DC transfer potency of infectious molecular clones
(IMCs) expressing the breast milk virus env variants
4403 bmC5 and 1209 bmH5 and produced either in per-
ipheral blood mononuclear cells (PBMC) or in 293 T
cells. The mean transfer efficiency of the 4403 bmC5
IMCs produced in PBMC and 293 T cells was 0.3%
(range 0.1 to 0.6) and 0.5% (range 0.1 to 0.6), respectively.
The mean transfer efficiency was also very similar for the
1209 bmH5 IMCs (PBMC: mean 0.6%; range 0.3 to 1.4
and 293 T: mean 0.5%, range 0.1 to 0.9). This data suggests
that the in vitro DC-mediated virus transfer efficiency of
the breast milk HIV Env variants produced in 293 T is
representative of viruses produced in host primary cells.
No difference in efficiency of viral entry between Env
variants from milk of postnatally-transmitting and
nontransmitting mothers and plasma of postnatally-
infected infants
We next investigated potential differences in viral entry
and efficiency of coreceptor usage between milk Env var-
iants from postnatally-transmitting and nontransmitting
women and postnatally-infected infants. First, we deter-
mined the infectivity of the Env pseudovirions in TZM-blcells. To control for the efficiency of the transfection reac-
tion employed to produce the Env pseudoviruses, the in-
fectivity ratio was calculated by dividing the TCID50/ml
determined in TZM-bl reporter cells by the p24 content
of each Env pseudovirus stock [33] (Figure 5A). There was
no difference in the infectivity of Env pseudoviruses from
the milk of transmitting mothers when compared to those
in milk of nontransmitting women (p=0.38). Similarly the
infectivity of Env variants from postnatally infected infants
was comparable to that of Env variants from the milk of
nontransmitting women (p=0.64). There was also no dif-
ference in the ability of the fusion inhibition T20 peptide
to inhibit the infectivity of Env pseudovirions from either
transmitting mothers (p=0.75) or infant (p=0.9) as com-
pared to Env variants from nontransmitting mothers
(Figure 5B). As previous studies have reported a bias to-
ward CCR5 usage in T/F viruses [19,48], we investigated
the coreceptor tropism of breast milk variants and infant
T/F variants. All the Env variants had a CCR5 tropism as
determined by a reduction/ absence of TZM-bl cell infec-
tion in the presence of the CCR5 antagonist TAK-779, but
not in the presence of the CXCR4 antagonist AMD-3100
(data not shown). The efficiency of CCR5 utilization by
the Env variants was assessed by incubating TZM-bl cells
increasing concentrations of the CCR5 antagonist, Mara-
viroc prior to infection (Figure 5C). The mean IC50 of
Maraviroc was not different between Env variants from
infants or transmitting mothers and variants from non-
transmitting mothers (p=0.36 and p=0.36). Finally, to
study the efficiency of CD4 engagement and postnatal
HIV transmission, we measured inhibition of the milk and
AC D
B
Figure 5 No difference in the efficiency of viral entry between Env virus variants from the milk of transmitting and nontransmitting
women, or postnatally infected infants. (A) Infectivity ratio (TCID50/ml divided by p24 amount in ng/ml) of Env virus variants; (B) Inhibition of
Env virus variant infectivity by CCR5 antagonist Maraviroc; (C) Inhibition of membrane fusion by entry inhibitor T20 peptide. Lines represent
means IC50s (performed in duplicate for each virus) for each group of Env variants.
Fouda et al. Retrovirology 2013, 10:3 Page 8 of 20
http://www.retrovirology.com/content/10/1/3infant Env pseudoviruses infectivity by soluble CD4
(sCD4) and CD4-Ig. There was no statistical difference in
the mean sCD4 IC50 of Env variants of transmitting and
nontransmitting women (p= 0.27) (Figure 5D). Similarly,
infant Env viruses variants were comparably sensitive to
sCD4 as nontransmitting Env variants (p= 0.45). Thus,
postnatally-transmitted Env variants do not appear to be
more efficient at viral entry than viruses in milk of non-
transmitting mothers.Env variants from milk of postnatally-transmitting and
nontransmitting mothers and postnatally-infected infants
are equally-sensitive to neutralization by autologous
plasma and milk
Early studies of vertically-transmitted viruses indicated
that viruses transmitted during breastfeeding are gener-
ally resistant to neutralization by autologous maternal
plasma [11,27]. Therefore, we measured autologous
plasma and milk neutralization of Env pseudoviruses
from milk of transmitting mothers and nontransmitting
mothers. Because breast milk from uninfected women
possesses low potency HIV-1 inhibitory activity [49,50],
breast milk neutralization was considered positive if the
neutralization titer was greater than 3 standard deviation
above the mean ID50 of three HIV-negative milk sam-
ples. Eleven of 14 milk Env pseudoviruses from transmit-
ting mothers were neutralized by autologous plasma
(Table 2) and 13 of 15 milk Env variants from nontrans-
mitting mothers were neutralized by autologous plasma(p=0.65), whereas only two milk Env variants from
transmitting women and four milk Env variants from
nontransmitting women were neutralized by autologous
milk (p=0.65). Interestingly, the most potent autologous
neutralization activity was observed against the milk Env
variant that is related to the transmitted variant from
the milk of subject 1209 (1209 bmH5) (Figure 1), with
ID50 of 2079 and 202 in plasma and milk, respectively.
In contrast, the T/F variant in milk of a transmitting
mother (4403 bmC5) was relatively resistant to
neutralization by autologous plasma (ID50=25) and milk
(ID50<5). Together, our data suggest that viruses in the
milk of postnatal-transmitting women are not inherently
more resistant to neutralization by autologous maternal
plasma or milk than viruses from the milk of nontrans-
mitting women.Breast milk Env variants from transmitting women and T/
F postnatal infant Env variants are equally-sensitive to
neutralization by broadly-neutralizing monoclonal and
polyclonal antibodies as milk Env variants of
nontransmitting mothers
We next examined the sensitivity of milk and infant Env
pseudoviruses to broadly-neutralizing mAbs including
4E10, 2F5, 2G12, PG9 and PG16 (Figure 6). As previously
reported for clade C viruses [51,52], most of the Env var-
iants were resistant to neutralization by 2F5 and 2G12 at
the highest tested concentration of 25 μg/ml (Figure 6).
Only three viruses (two from a transmitting and one from
Table 2 Neutralization of breast milk viruses by autologous plasma and breast milk
Plasma Breast
Milk1, 2
Uninfected
milk1
Uninfected
milk 2
Uninfected
milk 3
3305 BMC1 Nontransmitting 20 <5 6 16 12
3305 BMC9 Nontransmitting 38 <5 10 17 26
3305 BMC11 Nontransmitting 22 <5 5 15 11
3305 BMF4 Nontransmitting <20 5 12 48 32
3305 BMF6 Nontransmitting 30 6 12 15 39
0301 BMA2 Nontransmitting 45 5 5 5 26
0301 BMA6 Nontransmitting 24 4 <5 8 31
0301 BMA12 Nontransmitting 83 31 24 8 86
4707 BMF8 Nontransmitting 42 56 8 19 21
4707 BM H2 Nontransmitting 32 27 14 23 17
702 BMB4 Nontransmitting <20 77 18 9 20
702 BMB9 Nontransmitting 26 54 17 17 28
702 BMH12 Nontransmitting 36 56 22 29 32
5807 BMD1 Nontransmitting 44 <5 7 <5 <5
5807 BME7 Nontransmitting 24 <5 7 <5 <5
4403 BMB6 Transmitting 28 <5 <5 12 6
4403 BMB10 Transmitting 30 <5 <5 12 6
4403 BMC5 Transmitting 25 <5 <5 12 10
4403 BMG1 Transmitting 22 <5 <5 15 5
4403 BMH22 Transmitting 117 53 <5 10 <5
1209 BMA5 Transmitting 451 39 44 9 8
1209 BMB21 Transmitting 50 13 41 10 9
1209 BMG5 Transmitting 429 22 50 10 19
1209 BMH5 Transmitting 2079 202 22 7 <5
0404 BMB9 Transmitting 27 9 24 7 6
0404 BMD4 Transmitting 33 16 42 17 16
0404 BMF3 Transmitting <20 7 64 16 10
0404 BMG3 Transmitting <20 <5 10 6 35
0404 BMH4 Transmitting <20 <5 15 <5 <5
1Neutralization above the cut off of 3 standard deviations above the inhibitory dilution 50% of milk of uninfected mothers or plasma from uninfected individuals
is bold and italic. 2Numbers indicate inhibitory dilution 50%.
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4 viruses were neutralized by 2F5 (one from a transmitting
and three from nontransmitting mothers). In contrast,
most Env variants were sensitive to neutralization by the
other mAbs (Figure 6). There was no statistical difference
in the median IC50 of 4E10 between Env variants from
either infants or milk of transmitting mothers as com-
pared to variants from milk of nontransmitting mothers
(p= 0.88 and p=0.39 respectively). Similarly, the median
IC50 of PG9 and PG16 was not different between either
Env variants from postnatally infected infants (p= 0.56
and p=0.24 respectively) or transmitting women (p=0.67
and p=0.4, respectively) and those of nontransmitting
women. The sensitivity of the mother and infant Env var-
iants to HIVIG-C, a pool of HIV-1 specific IgG from cladeC infected individuals with broad neutralizing activity was
also evaluated. All Env variants from transmitting mothers
were neutralized by HIVIG-C whereas Env variants from
two of five nontransmitting women had milk viruses that
were resistant to neutralization at the highest concentra-
tion of HIVIG-C tested (625 μg/ml). Moreover, infant T/F
Env variants were significantly more sensitive to
neutralization by HIVIG-C than milk variants from non-
transmitting mothers (median IC50 71.69 μg/ml versus
255.5 μg/ml, p= 0.01). However, this difference only
trended towards significance when correcting for multiple
comparisons (q = 0.06). Thus, the postnatally-transmitted
infant viruses in our cohort were relatively sensitive to
neutralization by broadly-neutralizing polyclonal and
monoclonal Abs.
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IC50: 1-25 IC50: 0.1-1  HIVIG-C IC50: <625
2G12 2F5 4E1O PG-9 PG-16 VRC01 3BMC117 NIH 45-46 B12 CH31 VRC03 VRC04 HIVIG-C
3305 bmC1 BM non-trans >25 >25 5.8 >25 >25 2.93 0.95 2.38 >25 2.49 1.91 3.17 > 625
3305 bmC9 BM non-trans >25 >25 17.1 >25 >25 3.47 0.49 2.27 >25 2.92 3.86 2.19 > 625
3305 bmC11 BM non-trans >25 >25 13.2 >25 >25 1.17 0.46 0.71 >25 1.86 4.74 2.19 255.5
3305 bmF4 BM non-trans >25 >25 8.4 >25 >25 5.47 1.14 1.21 >25 4.03 >25 4.09 > 625
3305 bmF6 BM non-trans >25 >25 14 >25 >25 2.21 0.87 2.78 >25 2.1 2.14 3.09 > 625
0301 bmA2 BM non-trans >25 10 16.9 0.91 0.18 5.37 0.07 >25 >25 0.06 >25 4.3 96.4
0301 bmA6 BM non-trans >25 9.8 12.2 0.91 2.1 2.18 0.39 0.75 >25 22.62 >25 8.39 45.37
0301 bmA12 BM non-trans >25 8.3 10.1 0.66 4.6 16.2 0.38 >25 >25 13.54 >25 >25 77.59
4707 bmF8 BM non-trans >25 >25 >25 0.18 0.01 >25 >25 >25 >25 >25 >25 >25 > 625
4707 bmH2 BM non-trans >25 >25 >25 0.02 0.1 >25 >25 >25 >25 >25 >25 >25 395.88
0702 bmB4 BM non-trans >25 >25 5.6 0.83 0.12 0.41 0.11 0.88 >25 0.02 >25 0.06 358.84
0702 bmB9 BM non-trans >25 >25 3.6 0.38 0.04 >25 >25 >25 >25 10.45 >25 0.77 385.76
0702 bmD1 BM non-trans >25 >25 0.33 0.18 0.02 2.42 0.12 >25 >25 0.03 >25 0.04 23.5
0702 bmH12 BM non-trans >25 >25 4.75 0.37 0.13 >25 >25 >25 >25 0.29 >25 1.31 496.67
5807 bmE7 BM non-trans >25 >25 >25 0.03 0.01 0.29 0.15 0.13 >25 0.6 0.24 0.68 356.09
5807 bmD1 BM non-trans 8.77 >25 >25 2.67 >25 2.1 0.17 12.52 >25 0.37 >25 0.56 81.57
4403 bmB6 BM trans >25 >25 >25 0.6 0.89 0.06 >25 0.03 >25 >25 0.05 >25 131.8
4403 bmB10 BM trans >25 >25 >25 0.42 0.35 0.05 >25 0.02 >25 >25 0.05 >25 92.66
4403 bmG1 BM trans >25 >25 >25 0.24 0.25 0.13 >25 0.04 >25 >25 0.13 >25 78.87
4403 bmH22 BM trans >25 >25 17.76 7.5 >25 1.47 0.79 1.83 >25 1.47 0.59 4.88 62.96
1209 bmA5 BM trans >25 >25 1.16 >25 >25 >25 >25 >25 >25 >25 >25 >25 144.28
1209 bmB21 BM trans >25 >25 20.53 0.94 6.53 >25 >25 >25 13.25 >25 >25 >25 163.92
1209 bmG5 BM trans 0.84 >25 1.69 0.77 0.5 >25 >25 >25 4.27 >25 >25 >25 147.97
1209 bmH5 BM trans >25 >25 3.56 0.04 0.01 >25 >25 >25 >25 >25 >25 >25 186.69
0404 bmB9 BM trans 9.72 16.24 0.95 0.08 <0.01 0.4 0.05 0.04 3.2 1.46 6.49 1.17 139.22
0404 bmD4 BM trans >25 >25 >25 6.87 0.09 14.11 2.46 >25 >25 2.21 >25 5.85 114.64
0404 bmG3 BM Trans >25 >25 >25 0.58 0.25 0.07 0.07 0.12 >25 5.02 1 0.34 564.19
0404 bmF3 BM trans >25 >25 14.38 0.04 0.01 0.51 0.09 0.13 >25 0.65 0.64 0.35 150.27
0404 bmH4 BM trans >25 >25 >25 0.01 0.01 0.49 0.08 0.14 >25 0.59 0.28 0.27 149.56
BF1677 infant T/F >25 >25 >25 1.06 >25 1.5 0.2 4.72 >25 0.43 >25 >25 103.89
BF1266 infant T/F >25 >25 13.36 0.02 <0.01 0.05 >25 >25 >25 0.13 0.05 >25 93.65
BF942 infant T/F >25 >25 0.75 0.06 0.03 >25 0.02 0.02 >25 >25 >25 >25 65.05
BF591 infant T/F >25 >25 5.78 0.17 0.03 0.08 0.01 0.04 8.88 0.16 >25 0.27 71.69
BF703 infant T/F >25 >25 7.52 0.43 0.03 0.15 >25 0.33 >25 0.06 >25 0.58 59.35
BF329 infant T/F >25 >25 17.11 <0.01 <0.01 0.01 0.22 0.41 >25 7.62 >25 >25 11.23
4403 bmC5 infant T/F >25 >25 >25 0.58 1.65 0.05 >25 0.01 >25 >25 0.02 >25 154.68
Anti-CD4bs mAbs
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Figure 6 Neutralization sensitivity of Env variants from breast milk of postnatally transmitting or nontransmitting women and of
infant T/F Env variants to broadly neutralizing polyclonal and monoclonal antibodies.
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http://www.retrovirology.com/content/10/1/3Postnatally-transmitted infant viruses are sensitive to
neutralization by broadly-neutralizing mAbs against the
CD4 binding site
It was recently reported that T/F clade B viruses are more
sensitive to neutralization by anti-CD4 binding site (bs)
mAbs b12 and VRC01 than chronic viruses [20]. There-
fore, we investigated the sensitivity of postnatal T/F infant
and breast milk Env variants to inhibition by a panel of
broadly-neutralizing mAbs against the CD4 bs including
b12, CH31, 3BNC 117, NIH 45–46, VRC01, VRC03 and
VRC04 (Figure 6). Binding of the mAbs 3BNC117,
NIH45-46 and VRC01 to the CD4 bs induces a conform-
ational change that enhances the binding of CD4-induced
mAbs (such as 17B) to their epitopes in the co-receptor-
binding region of gp120; whereas CH31, VRC03, VRC04and b12 do not induce this conformational change
[21,53]. xEnv pseudoviruses from milk of transmitting and
nontransmitting mothers were equally sensitive to
neutralization by VRC01 and CH31 (p = 0.81 and 0.83, re-
spectively). Moreover, postnatal-T/F variants were also
equally sensitive VRC01 and CH31 compared to milk Env
variants from nontransmitting women (p = 0.45 and 0.9,
respectively). Importantly, 6 of 7 T/F infant viruses
were neutralized by VRC01 and NIH 45–46 (Figure 6),
suggesting that postnatally-transmitted infant viruses are
generally sensitive to neutralization by anti-CD4 bs
broadly-neutralizing mAbs. The sensitivity of the majority
of infant viruses to the new generation of anti-CD4 bs
mAbs indicates that these reagents could be useful in the
prevention of postnatal HIV-1 transmission.
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Assessing the genetic and functional characteristics of
transmitted HIV-1 Env variants isolated from donors
and recipients is important to identify any biological sig-
natures associated with mucosal transmission that can
be exploited in the design of prophylaxis strategies. To
gain insights into the biologic properties of viruses cap-
able of breaching the infant gastrointestinal mucosa dur-
ing transmission through breastfeeding, we isolated and
produced 30 Env variants from the breast milk of 8
HIV-1-infected women who did or did not transmit
HIV-1 to their infants postnatally and investigated their
genetic and phenotypic characteristics. In addition, T/F
Envs from 7 infants infected through breastfeeding were
also studied. This represents one of the largest pheno-
typic comparative analyses of postnatally-T/F variants
and uniquely compares their virologic phenotype to
nontransmitted breast milk Env variants.
Several studies have attempted to identify genetic dif-
ferences between chronic and transmitted viruses, with
disparate results. The majority have reported that acute
viruses have shorter variable loops and fewer glycosyla-
tion sites than chronic viruses [9,13,14,54]. However,
while comparing sequences from clade B chronic (n=24)
and T/F envs (n=17), Wilen and collaborators [20] found
no genetic signatures associated with transmission.
Interestingly, a larger sequence analysis of clade B env
gene sequences allowed for the identification of a small
number of signature sequences that could influence Env
incorporation and viral entry [16]. In this study, we
found that based on the Env V2 sequence, all infant T/F
variants and most maternal milk variants are likely to
have been susceptible to the potentially-protective V2-
specific antibody responses elicited by the RV144 vac-
cine. Moreover, we observed that a previously-identified
unique sequence (isoleucine at position 6) in the signal se-
quence of the env gene of placentally-transmitted clade C
variants [37] was common in Env variants of postnatal-
transmitting women and postnatally-infected infants, al-
though the observed high frequency of this mutation
could be due to the relatively small number of mothers
and infants included in the study. The location of this sig-
nature amino acid in the signal sequence of the Env gene
is not likely to affect the structure or interactions of the
Env protein, but could affect the efficiency of Env produc-
tion. Association of an Env signature sequence with more
than one MTCT route may indicate that this unique se-
quence provides a fitness advantage to the virus in the in-
fant [12]. Therefore, it would be important to analyze this
putative genetic signature in the env signal sequence in a
larger panel of both clade B and C MTCT T/F envs.
The ability of HIV-1 virions to perform key steps
required to cross the infant gastrointestinal epithelial
barrier could contribute to restricting the number offounder viruses. We tested this hypothesis by measuring
the interaction of milk Env variants with intestinal epi-
thelial cells. Further, we assessed the ability of gp120
from these Envs to bind to Galcer, the putative epithelial
cell attachment factor for HIV-1 [38]. Milk Env variants
from transmitting and nontransmitting women had
an equally low efficiency epithelial cell attachment and
Galcer binding. These results are in accordance with
previous reports of low level of transcytosis across epi-
thelial barriers [55-57]. However, previous studies have
reported that Galcer binds efficiently to both gp120 and
gp41 [58-60]. The interaction of the HIV Env with Gal-
cer may be dependent on conformational epitopes and
multivalent interactions. Thus, future work should inves-
tigate the binding of monomeric and polymeric gp140 of
transmitted variants to Galcer liposomes.
Previous studies have indicated that DCs are present
in infant oral and intestinal sub-mucosa [61]. The bind-
ing of HIV virions to these cells and their transfer to
CD4+ cells may be an important step in the establish-
ment of mucosal HIV-1 infection [39], especially in the
setting of postnatal transmission, as carbohydrates in
milk may compete for interaction with lectin-binding
molecules on DCs [43,62]. While there appeared to be
lower DC-binding efficiency of postnatally-T/F Env
variants compared to those in milk of nontransmitting
women, the efficiency of DC-mediated virus transfer
was not different between the transmitted and nontrans-
mitted variants. The direct correlation between DC-
mediated trans-infection efficiency and number of
O-linked glycosylation sites suggests that this function
may more dependent on glycan:DC interactions. In this
study TZM-bl cells were used as target cells instead of
primary CD4 + T cells, which may better represent
in vivo function, in order to assure reproducibility and
comparability across assays. Our results are similar to
those of Wilen and collaborators [20] who reported no
difference DC trans-infection efficiency between chronic
and T/F clade B viruses from sexual transmission. There-
fore, the ability of transmitted Env variants from other
MTCT transmission routes and other virus subtypes
should be investigated to determine if efficient DC to CD4
+ T cell transfer is a particular feature of HIV-1 MTCT.
Of note, the Env pseudoviruses and recombinant Env pro-
teins used in these studies were primarily produced in
293 T cells, which may yield distinct glycosylation patterns
compared to primary cells. Thus, these investigations
mainly address functional differences in transmitted and
nontransmitted Env variants at the amino acid level. How-
ever, a comparison of DC transfer efficiency of two breast
milk full length, replication-competent Env variants
revealed similar transfer efficiencies, suggesting that the
Env variants produced in 293 T cells are representative of
those produced in primary host cells in this assay.
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derived macrophages (MDM) [18,63] and primarily
utilize CCR5 [18-20,48]. In accordance with previous
reports, all the postnatal T/F Env variants were CCR5-
tropic viruses, and there was no difference in CCR5
utilization between transmitted and nontransmitted milk
variants. Moreover, CD4 utilization and infectivity in
TZM-bl cells were comparable between transmitted and
nontransmitted milk variants. Thus, our results suggest
no difference in viral entry mechanisms between infant
postnatal T/F and milk nontransmitted Env variants.
Maternal antibodies are transferred to the fetus during
pregnancy and, at birth, infants born to HIV-1 infected
women have high levels of HIV-specific antibodies
[30,64]. Furthermore, HIV Env-specific functional anti-
bodies are present in the milk of HIV-infected women
[31,65]. These maternal antibodies may provide some
protection from HIV acquisition [32,65-67]. However,
studies have found conflicting results regarding associa-
tions between maternal and infant antibody responses
and MTCT, probably related to differences in modes of
transmission and virus clades being assessed [30,68].
Maternal neutralizing antibodies may also exert selective
pressure on viruses that could contribute to the trans-
mission bottleneck. In support of this hypothesis, previ-
ous studies reported that viruses transmitted during
breastfeeding are usually resistant to maternal autolo-
gous neutralization [27,32]. However, other studies did
not observe increased resistance of infant viruses to
neutralization by maternal plasma [14,63,69,70]. Further-
more, no difference in sensitivity to autologous neu-
tralization was observed between clade C viruses from
postnatally-infected infant and viruses from their mothers
[28]. Accordingly, we also found no difference in autolo-
gous milk or plasma neutralization of milk Env variants
from women who did or did not transmitted HIV to their
infants postnatally. In addition, most Env variants from
women who transmitted HIV to their infants through
breastfeeding and from postnatally infected infants were
sensitive to neutralization by the new generation of
highly-potent broadly neutralizing mAbs (PG9, PG16,
VRC01, and CH31). Thus, our results, together with other
recent reports, suggest that neutralization-resistance may
not be a defining feature of HIV-1 clade C viruses trans-
mitted during breastfeeding.
Our inability to discern major differences in the geno-
type and phenotype of postnatal-T/F variants could sup-
port that crossing the epithelial barrier is a stochastic
event that does not depend on specific biologic properties
of the Env. Fortunately, animal studies have established
that infusion of broadly-neutralizing antibodies can pro-
tect the infant against postnatal HIV-1 acquisition [26].
Thus, an infant vaccine to prevent HIV-1 transmission
through breastfeeding would have to induce rapidly-elicited protective antibodies to ensure safe breastfeeding.
Interestingly HIV vaccination of infants born to HIV
infected women induces immune responses distinct from
that of their mothers [71]. As infant immune response
could take weeks to be established, maternal vaccination
to elicit antibody responses in breast milk and/or passive
infusion of the infant with broadly-neutralizing, protective
mAbs could assure undisrupted protection of infants
throughout the breastfeeding period. Interestingly, passive
immunotherapy with broadly-neutralizing mAbs against
the CD4 binding site in infant rhesus monkeys was shown
to accelerate the development of functional antibody
responses following SIV infection [72]. Thus, passive ad-
ministration of specific mAbs prior to infant vaccination
might also be beneficial for the induction of the rapid im-
mune responses needed in the setting of breast milk
transmission.
Conclusions
We have investigated the biologic characteristics of 36
HIV-1 variants from either the breast milk of HIV-1
infected mothers or from postnatally-infected infants.
We did not find a genotypic or phenotypic characteristic
unique to infant postnatal T/F viruses. Similarly, no clear
genetic or functional differences were observed between
milk Env variants of women who transmitted or did not
transmit HIV postnatally to their infants. Importantly,
most infant Env variants (6–7 out of 7) were neutralized
by VRC01, PG9, and PG16, indicating that they are good
candidates for infant passive immunization. Thus, these
mAbs should be investigated for their ability to prevent
postnatal HIV-1 transmission.
Methods
Study population
Pregnant women testing HIV-positive by rapid antibody
test were recruited from two rural health clinics outside
Blantyre, Malawi as part of the CHAVI 009 protocol be-
tween November 2007 and November 2008, as previ-
ously described [31,33]. Women were enrolled at
delivery if HIV-1 infection was confirmed by detection
of plasma HIV-1 RNA and breastfeeding was initiated.
Except for single dose nevirapine at delivery, the women
included in this study remained off antiretroviral therapy
during lactation. The mothers were counseled to exclu-
sively breastfeed and weaned their infants between 6 and
9 months of age, per WHO recommendations during
that time. HIV-1 env gene variants were sequenced and
cloned from milk and infant plasma collected four to six
weeks post-delivery from three women who transmitted
HIV-1 postnatally to their infants and from five HIV-
infected women, matched by peripheral CD4 count and
breast milk HIV-1 RNA load, who did not transmit the
virus to their infant. Env gene sequences from six
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in Pregnancy prospective cohort [9,73-76] infected with
HIV-1 during breastfeeding (HIV-1 DNA negative by
real-time PCR at 0 and 6 weeks, positive at 12 weeks)
were also included [35]. Both studies were approved by
the College of Medicine Research and Ethics Committee
in Malawi and institutional review boards at each of the
participating institutions where samples were received or
processed for end-user analysis.
HIV-1 env gene single genome amplification and cloning
Breast milk supernatant aliquots of 1 ml were concen-
trated 10 fold by centrifugation at 23,600 × g for 1 h at
4°C (final volume 100 μl), and RNA was extracted. De-
pending on the milk virus RNA load, between 200 and
10,000 RNA copies were reverse transcribed. Plasma
viral RNA and cell-associated DNA were also extracted
from blood samples collected 12 weeks after delivery
from postnatally-infected infants. Single-strand cDNA
was synthesized using the SuperScript III protocol
according to the manufacturer’s instructions (Invitrogen
Life Technologies) and either used immediately for PCR
or stored frozen at −80°C. Full-length env genes were
PCR amplified by single genome amplification (SGA)
methods as previously described [19]. Briefly, cDNA was
titrated by endpoint dilution (undiluted to 1:40 dilution
for breast milk cDNA) in 96-well PCR plates to a concen-
tration that yielded no more than 30% PCR positive wells
and conforms to a Poisson distribution of a single tem-
plate per reaction. All milk env sequences used in this
study are deposited in GenBank [accession numbers
HM070449 to HM070824 and HQ595810 to HQ596189].
Phylogenetic sequence analysis
Breast milk env sequences showing significant evidence of
APOBEC-driven G-to-A hypermutation, according to the
Los Alamos National Laboratory (LANL) HIV Sequence
Database tool Hypermut 2.0 [77] (http://www.hiv.lanl.gov/
content/sequence/HYPERMUT/hypermut.html), were ex-
cluded from the phylogenetic analyses. Sequence align-
ments were produced using ClustalW [78] and were
subsequently adjusted to optimize codon alignment.
Regions that could not be aligned unambiguously were
omitted in further phylogenetic analyses but were
included in all other genetic and phenotypic analyses of
the virus populations. A phylogenetic tree including
sequences from all 8 subjects indicated that the sequences
corresponding to each subject clustered with high boot-
strap support (100% [data not shown]) [78]. For each sub-
ject, a maximum likelihood phylogenetic tree was inferred
using PhyML, version 3.0 [79], and the results of approxi-
mate likelihood ratio tests (≥0.95) were used to infer
phylogenetic support [80]. For the infant plasma env
sequences, the number of viruses and genetic identity ofthe env gene responsible for establishing productive
clinical infection in each infant was determined by
SGA and a mathematical model of random evolution,
as previously described [33] using the Poisson-Fitter
tool (http://www.hiv.lanl.gov/content/sequence/POISSON_
FITTER/poisson_fitter.html). Briefly, infant plasma env
sequences (n=9-29 amplicons per sample) were highly
homogeneous in all infants by highlighter plot analysis
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/
highlighter_top.html), except one infant (infant of 1209), in
which plasma was not available for SGA until 6 months
after infection, and conformed to a model of random evolu-
tion and coalesced to a single consensus. The consensus of
the T/F env sequence in the postnatally-infected infant
plasma at twelve weeks of age was cloned into pcDNA3.1
directional TOPO expression vector (Life Technologies),
grown in TOP10 competent cells, sequence confirmed, and
used in transfection of 293 T cells to generate Env variant
pseudovirions. The number of days that would be required
by the most recent common ancestor to reach the env di-
versity observed in the 12-week infant blood sample was
also calculated using the Poisson-fitter tool. Based on model
predictions, the selected infant env gene was calculated to
have been transmitted <90 days from the time the plasma
sample was obtained, conforming to the timing of these
postnatal transmissions [35].
Sequence genotype/phenotype analysis
Assessment of previously-defined T/F Env signature
patterns [16] was accomplished by alignment of the infant
and maternal env sequences with the HXB2 reference
sequence using the HIValign program at the LANL website
(http://www.hiv.lanl.gov/content/sequence/VIRALIGN/
viralign.html) for standard nucleotide position number-
ing. Potential N-linked sites were enumerated using the
N-glycoSite tool from the Los Alamos National Laboratory
(LANL) website (http://www.hiv.lanl.gov/content/sequence/
GLYCOSITE/glycosite.html) which locates putative N-
glycosylation sites in an amino acid sequence. An estimate
of the number of O-linked glycosylation sites was carried
out using the NetPhos program from the Center for
Biological Sequence Analysis website (http://www.cbs.dtu.
dk/services/NetPhos/). Putative phosphorylation sites with
a predicted score greater than 0.5 were defined as probable
O-linked glycosylation sites.
Env pseudoviruses preparation
Env pseudoviruses were prepared by transfection in
293 T cells with 4 μg of env plasmid DNA and 8 μg of
env-deficient HIV-1 plasmid DNA (SG3Δenv) using the
FuGENE 6 transfection reagent (Roche Diagnostic). For
autologous neutralization assays, a mutated backbone
resistant to reverse transcriptase inhibitors (1617RT/
K103N, obtained from Ron Swanstrom) was used. Two
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ing pseudoviruses was harvested, filtered, aliquoted and
stored at −80°C. An aliquot of frozen pseudovirus was
used to measure the infectivity in TZM-bl cells. Serial
five-fold dilutions of pseudovirus were distributed in
quadruplicates to 96 well flat bottom plates (Costar) in a
total volume of 100 μl per well. Then, freshly trypsinized
TZM-bl cells were added (10,000 cells/ well in DMEM
10%FBS containing HEPES and 10 μg/ml of DEAE-dex-
tran). After 48 hours of incubation at 37°C, 100 μl of
cells/well were transferred to 96-wells black solid plate
(Costar) and the luminescence measured using the Bright
Glo luminescence reporter gene assay system (Promega).
Wells producing relative luminescence units > 3x back-
ground TZM-bl luminescence were scored as positive and
the TCID50 was calculated by the method of Reed and
Muench, as previously described [81]. Out of a total of 43
Env variants produced, only HIV-1 Env pseudoviruses that
produced functional infectious Env-pseudotyped variants
(TCID50 > 1000/ml in TZM-bl reporter cells) (n = 14
from transmitting mothers, n = 16 from nontransmitting
mothers and n=6 from postnatally infected infants) were
used in functional assays.
Epithelial cell binding
A modified protocol from Mantis et al. [82] was used to
measure the binding of Env variants to the colonic cell
line HT-29 (ATCC). Briefly, HT-29 were grown to con-
fluence on collagen-treated 96 well flat bottom plates in
Modified McCoy’s 5a Medium supplemented with 10%
Fetal Bovine Serum (FBS) and antibiotics. The cells were
washed twice, then Env variants diluted in serum-free
media were added in triplicate and the plates were incu-
bated at 37°C for 3 hours. To determine the amount of
virus bound to cells, the cells were washed 3 times with
DPBS (Gibco) to remove free virus, detached with Try-
pLE (Invitrogen), and lysed with Triton-X 100. Levels of
p24 were measured in cell lysates by commercial ELISA
(Perkins-Elmer) according to the manufacturer protocol.
Binding efficiency was calculated by dividing the amount
of p24 recovered by the p24 input measured in the same
ELISA. Results from two independent assays performed
in triplicate were averaged. For Env dependency assay,
HIV BAL was incubated either with growth media, mAb
IgG1B12 (25 μg/ml) or the control antibody synagis
(25 μg/ml) for 1 hour at 37°C prior to addition to the cells.
Production of gp120 Env variants
Codon-optimized gp120 env genes were commercially-
synthesized (Genewiz, Inc.) and cloned into the
pcDNA3.1+ expression vector (Invitrogen). The expres-
sion vectors containing env gene inserts were used for
polyethyleneimine-mediated transfection of 293 T cells.
The resulting recombinant Env gp120 glycoproteinswere purified from supernatants of transfected 293 T cell
cultures using Galanthus nivalis lectin-agarose column
chromatography (Vector Labs) and analyzed by SDS-
polyacrylamide gel electrophoresis and by western blot
with the anti-HIV-1 Env monoclonal antibody VRC C
16H3. Monomers of the gp120 proteins were isolated
from their oligomers by Fast Protein Liquid Chromatog-
raphy (FPLC) and stored at −70°C until use.
Binding of gp120 Env variants to Galcer
The lipids 1- palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC) and D-galactosyl-β-1,1’ N-octanoyl-D-
erythro-sphingosine (Galcer) (Avanti Polar Lipids) were
used to make liposomes using extrusion technique, as
described earlier [83,84]. Appropriate volumes of stock
solutions of POPC (dissolved in chloroform) or Galcer
(dissolved in chloroform:methanol 70:30 v/v) and POPC
in a 1:1 molar ratio were mixed . The lipid mixture was
dried in a stream of gaseous nitrogen and any residual
solvent was removed by drying the lipids film under a
vacuum overnight. The dried lipid mixture was hydrated
with PBS buffer (pH 7.4) and incubated at 60°C for
45 minutes, prior to sonication with an ultrasonic liquid
processor (Misonix, Inc), and extrusion through 0.4 μm
and 0.1 μm polycarbonate membranes using a mini-
extruder (Avanti Polar Lipids). The binding of breast
milk HIV-1 gp120 monomers to Galcer was performed
by Biolayer Interferometry Technique using a ForteBio
OctetRed instrument and Aminopropylsilane (APS) bio-
sensors. Briefly, the Galcer and POPC liposomes
(250 μM placed in the sample plate well) were loaded
onto APS biosensors by dipping them into sample plate
wells containing 250 μM of liposomes for 10 minutes.
As a control, an APS sensor was dipped into a well con-
taining PBS buffer. The blank and liposome-loaded APS
sensors were washed in PBS for 1 minute. In order to
minimize non-specific interaction of breast milk HIV-1
gp120 monomers with the blank and liposome-loaded
APS sensors, the sensors were coated with bovine serum
albumin (BSA) by dipping into wells containing 0.1% BSA
for 5 minutes followed by a wash with PBS for 1 minute.
The interaction of HIV-1 gp120 monomers with Galcer
liposomes was measured by monitoring wavelength shift
(in nanometer). After 2 minutes dip in PBS to obtain
baseline, the blank and liposomes-loaded APS sensors
were dipped into wells containing gp120 monomers at a
100 μg/ml (or at the indicated) concentration for
30 minutes followed by a 10 minutes wash in PBS. The
signal from blank APS sensor was subtracted to obtain
signal specific to Galcer and POPC liposome binding. The
gp120 monomers either did not bind POPC liposomes or
bound extremely weakly. Any such weak binding to POPC
liposomes was subtracted from the Galcer liposome
binding to obtain Galcer specific binding.
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Renilla Luciferase expressing replication competent
HIV-1 proviral DNA was constructed as previously
described [85] to express the breast milk virus env vari-
ant sequences, 4403 bmC5 and 1209 bmH5. The plas-
mids were used to transfect 293 T cells using the FuGENE
6 transfection reagent (Roche Diagnostic). The cell culture
supernatant containing viruses was harvested after 48 and
72 hours, filtered, aliquoted and stored at −80°C. Viruses
produced in 293 T were used to infect human PBMC that
have been activated overnight with PHA-P. After 24 hours,
the culture supernatant was removed and fresh medium
was added. Virus production was monitored by p24 pro-
duction and the cell culture supernatant was harvested
was the p24 amount was ≥ 10 ng/ml, filtered, aliquoted
and stored at −80°C. Virus stocks produced in 293 T cells
and PBMC were evaluated for infectivity in TZM-bl cells.
DC binding and transfer
Peripheral Blood Mononuclear cells (PBMCs) were iso-
lated by ficoll-paque gradient centrifugation of fresh
whole blood from three to five donors per assay. A total
of 50 × 106 PBMCs per plate were cultured in 10-cm tis-
sue culture plates for 1-hr to initiate adherence selection
of monocytes. Cells from different donors were cultured
separately to avoid mixed leukocyte reactions. Culture
dishes were subsequently washed to remove non-adherent
cells. The monocytes were induced to differentiate into
immature dendritic cells (DC) by culturing them in the
presence of 200 IU/ml of IL-4 and 100 IU/ml GM-CSF for
5 days. The cytokines were refreshed on day 2 or 3 of
incubation. Immature DCs were harvested on Day 5 and
plated in 6-well plates at a concentration of 1.5 × 106 cells
per well. Lipopolysaccharide (LPS) at a concentration of
50 ng/ml was added as a maturation stimulus on day 6
and mature DCs were harvested on day 7.
On Day 6 of the DC maturation process, TZM-bl re-
porter cells were plated in 96 well plates. The reporter
cells were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH (Dr. John C. Kappes, Dr. Xiaoyun Wu and Tran-
zyme Inc). On Day 7, DCs were harvested, washed, and
resuspended in fresh media at 2,500,000 cells/ml for
binding assays and at 3,000,000 cells/ml for transfer
assays. A 100 μl aliquot of the cell suspension was added
to each experimental well. Triplicate wells were set up
for each experimental condition. 20–25 ng of p24 of
each Env pseudotyped virus, in a total volume of 100 μl,
was then added to each well. The DCs and virus were
co-cultured at 37°C for 2 hours. For antibody inhibition
assays, the virus was pre-incubated with 30 μg/mL
monoclonal antibody (mAb) (anti-HIV-1 Env mAb
2 G12 [86], CH08 [40] or anti-Respiratory Syncytial
Virus (RSV) mAb Syangis) for 30 minutes prior to co-culturing with the DCs. This concentration is similar to
the concentration of total IgG in breast milk in this
population (median 80 μg/ml range: 20 to 400 μg/ml
[31]. For the Env competition assay, the JRFL Env gp120
was pre-incubated with the DCs for 30 minutes at 37°C
prior to addition of the Env pseudovirus. For the anti-
lectin treatments with methyl-α-D-mannopyranoside
(C7H14O6; Sigma-Aldrich) and human lactoferrin
(Sigma-Aldrich), the DCs were pre-incubated with
0.5 M C7H14O6 or 100 μg/mL lactoferrin prior to
addition of the Env pseudovirus. After the 2 hour incu-
bation, the cells were washed 3 times with media to re-
move unbound virus. To measure DC-binding efficiency,
the cells were lysed with 0.5% Triton-X 100 prior to
quantification of the amount of bound virus using a
commercial p24 ELISA kit according to the manufac-
turer’s recommendations (Perkins-Elmer, Inc.). Binding
efficiencies were calculated by dividing the amount of
DC-bound p24 by the original p24 amount of the stock
virus added to the experimental well, measured in the
same p24 ELISA. To assess DC transfer efficiency, 11
two-fold serial dilutions of the washed DCs were pre-
pared in final volumes of 100 μl. The initial DC dilution
had a total of 150,000 cells/100 μl. The eleven DC dilu-
tions for each experimental condition were added to a
96-well plate with plated TZM-bl cells, with the last well
in each row serving as a virus-free experimental back-
ground control. Following 48 hour of co-culture incuba-
tion at 37°C, DC trans-infection of the TZM-bl cells was
detected using Bright-Glo luciferase assay system (Pro-
mega). The 50% Tissue culture infectious dose (TCID50)
for each experimental condition was calculated using the
method of Reed and Muench, with a cutoff for positive
wells set at two times the average of the background
wells for each respective plate. Transfer efficiencies were
calculated by dividing the TCID50 of the pseudovirus-
loaded DCs by the TCID50 of the stock pseudovirus used
in the experiment. Infectious pseudoviruses with un-
detectable DC transfer efficiencies (n = 5) were assigned
a transfer efficiency halfway between zero and the lowest
transfer efficiency detected in the study (0.027%) for
statistical analysis.
DC-SIGN mediated trans-infection
Parental 3 T3 and a 3 T3 cell line stably expressing
human DC-SIGN were obtained from the NIAID AIDS
Research and Reference Reagent Program [87]. Approxi-
mately 10,000 3 T3-DC-SIGN cells or parental 3 T3 cells
were plated for 24 hours in 100uL DMEM containing
10% FBS (Sigma). Prior to addition of HIV-1 Env pseu-
doviruses, cells were pretreated with 2 μg/μL Mannan
solution (Sigma) or DMEM media (Invitrogen) alone for
30 minutes at 37°C. Next, 5 ng p24 Env-pseudovirus was
added and cells were spinoculated for 2 hrs at 1000 X g
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with 200μL of media and co-cultured with 10,000 TZM-
bl cells for 48 hours. Co-cultured cells were then washed
with 100μL PBS, lysed with 1X Reporter Lysis Buffer
(Promega), and frozen at −80°C. Cells were frozen and
thawed three times prior to enumeration of luciferase
activity. Luciferase activity was monitored in GloMax 96
Microplate Luminometer (Promega) per manufacturer’s
instructions. All experiments were performed in triplicate
and data was normalized to the Env-pseudovirus TCID50.
The mannan-sensitive DC-SIGN-mediated transfer was
calculated by subtracting the transfer efficiency in the
presence of mannan from that in the absence of mannan.
Coreceptor usage
Coreceptor usage was determined in TZM-bl cells by
using TAK-779 (NIH HIV reagent repository), a CCR5
receptor antagonist, and AMD-3100 (NIH HIV reagent
repository), a CXCR4 antagonist. Freshly trypsinized
TZM-bl cells were distributed into 96-well plates
(10,000 cells/well in DMEM-10% FBS containing HEPES
and 10 μg/ml of DEAE-dextran) and incubated for
1 hour with either TAK-779 (10 μM), AMD-3100
(1.3 μM), a combination of the two reagents, or no in-
hibitor (control wells). Pseudoviruses were added to
wells with the different treatments in triplicate. After
48 hours of incubation, luminescence was measured.
Wells containing coreceptor inhibitors were compared
to control wells to determine if either agent led to a re-
duction in infectivity. Viruses known to use either CCR5
or CXCR4 were used a controls. For testing the effi-
ciency of CCR5 utilization, diluted preparations of the
CCR5 antagonist Maraviroc [88] were incubated with
TZM-BL cells for 1 hour then Env variants were added.
After 48 hours, luciferase expression was measured
(Bright-Glo, Promega) and the IC50 was calculated.
Fusion inhibition
The efficiency of viral entry by the different Env variants
was assessed in TZM-bl cells. Briefly, diluted preparations
of fusion inhibitor T20 peptide [89] (AIDS Research and
Reference Reagent Program) were incubated with TZM-bl
cells and Env-variants for 48 hours, then, luciferase ex-
pression was measured (Bright-Glo, Promega) and the
IC50 determined.
Virus neutralization
Virus neutralization assays were performed using the fol-
lowing reagents: mAbs 4E10, 2 F5, and 2 G12 purchased
from PolyMun; mAbs PG9 and PG16 provided by Dennis
Burton; mAbs 19B and 17B provided by Barton Haynes
and HIV-specific pool of IgG from HIV-1 clade C infected
individuals with broad neutralization (HIVIG-C) obtained
from David Montefiori. To examine sCD4 binding siteneutralization sensitivity the following reagents were used
sCD4 purchased from PolyMun, mAb IgG1B12 provided
by Dennis Burton, CD4-Ig and mAbs VRC01, VRC03,
VRC-PG04, NIH 45–46, 3BMC117, provided by John
Mascola and mAb CH31 provided by Barton Haynes. Au-
tologous virus neutralization was assessed with plasma
and milk samples from CHAVI009 patients collected 4 to
6 weeks after delivery. The autologous neutralizing re-
sponse against infant Env pseudoviruses was not assessed
because maternal plasma and breast milk samples were
not available. Prior to neutralization assessment, the
plasma samples were heat inactivated at 56°C for 1 hour
and the breast milk samples were delipidized by centrifu-
gation at 25,000 g at 4°C for 30 minutes and filtered using
spin X filter tubes (Fisher). The delipidized samples were
then concentrated 4 fold using Amicon Ultra centrifugal
filters with a 100 K cutoff. Neutralization was measured
by reduction in luciferase reporter gene expression after a
single round of infection in TZM-bl cells, as previously
described [90]. The 50% inhibitory dose (ID50) titer was
calculated as the plasma or milk dilution that caused a
50% reduction in relative luminescence units (RLU) com-
pared to the virus control wells after subtraction of cell
control RLUs. The 50% inhibitory concentration (IC50)
titer was calculated as the reagent concentration that
caused a 50% reduction in RLU.
Statistical analysis
A mixed model was applied to compare the difference
between the least square means of each virologic func-
tion of milk Env-variants of postnatal-transmitting
women and nontransmitting women, and between post-
natally-T/F infant Env variants and milk Env variants of
nontransmitting women. This method takes into ac-
count multiple observations (virus variants) within each
individual. In addition, Q values were calculated as a
false discovery rate correction for multiple comparison
[91]. Correlations between DC:virion interactions and
glycosylation sites were performed with a Spearman’s
rank correlation; and the Wilcoxon match-paired test
was used to compare DC transfer efficiency between
viruses produced in PBMC and 293 T cells. The Fisher’s
exact test was used to compare the proportion of viruses
that were sensitive to autologous neutralization.
Additional files
Additional file 1: Figure S1. HIV-1 env clones selected for functional
characterization from genetically-diverse viral variants found in breast
milk of eight chronically HIV-infected Malawian women (A-H). Maximum
likelihood phylogenetic trees for full-length HIV env RNA sequences
amplified by single genome amplification from milk (blue circles and
stars) and plasma (red circles) samples taken within 4-6 weeks
postpartum are depicted. Blue filled circles denote milk sequences from
the left breast, while blue stars indicate milk sequences from the right
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possible, from clusters of identical or near identical sequences (inferred to
define clonally-amplified variants) were cloned into an expression vector.
Milk Env clones that were functional (arrows) in a standard pseudotyping
assay were further characterized. Milk Env clones (2 to 5 per patient) from
three transmitting (D, G, and H) and five nontransmitting (A, B, C, E, and
F) women are depicted. In two transmitting women, the milk sequence
that was identical (4403_BMC5) or closest (1209_BMH5) to the virus that
infected the corresponding infant was identified and included in the
study. Numbers at the nodes indicate the level of support for tree
branches (likelihood ratio test values ≥0.095). The scale bar represents
0.01 substitutions per site.
Additional file 2: Figure S2. No difference in DC-SIGN binding
efficiency between T/F infant and breast milk Env virus variants. (A) DC-
SIGN mediated trans-infection efficiency of milk and infant Env virus
variants in the presence (black bar) and absence (grey bar) of mannan.
While mannan treatment generally reduced viral transfer to indicator
cells, a significant portion of the binding was not inhibited by mannan
treatment. Bars represent the mean transfer efficiency of three replicates,
error bars represent standard deviation. (B) Dot plot of the mannan-
inhibitable DC-SIGN transfer efficiency of Env virus variants from
transmitting and nontransmitting women, and postnatally-infected
infants. The line represents median normalized DC-SIGN transfer
efficiency for each Env-pseudovirus, grouped by transmission category.
Stars represent transmitted milk variants.
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